Summary
Esmolol is an ultra short-acting intravenous cardioselective β-antagonist. It has an extremely short elimination half-life (mean: 9 minutes; range: 4 to 16 minutes) and a total body clearance [285 ml/min/kg (17.1 L/h/kg)] approaching 3 times cardiac output and 14 times hepatic blood flow. The α-distribution half-life is approximately 2 minutes. When esmolol is administered as a bolus followed by a continuous infusion, onset of activity occurs within 2 minutes, with 90% of steady-state β-blockade occurring within 5 minutes. Full recovery from β-blockade is observed 18 to 30 minutes after terminating the infusion. Esmolol blood concentrations are undetectable 20 to 30 minutes postinfusion. The elimination of esmolol is independent of renal or hepatic function as it is metabolised by red blood cell cytosol esterases to an acid metabolite and methanol. The acid metabolite, which is renally eliminated, has 1500-fold less activity than esmolol. Methanol concentrations remain within the range of normal endogenous levels.
Clinically, esmolol is used for the following: (i) situations where a brief duration of adrenergic blockade is required, such as tracheal intubation and stressful surgical stimuli; and (ii) critically ill or unstable patients in whom the dosage of esmolol is easily titrated to response and adverse effects are rapidly managed by termination of the infusion. In adults, bolus doses of 100 to 200mg are effective in attenuating the adrenergic responses associated with tracheal intubation and surgical stimuli. For the control of supraventricular arrhythmias, acute postoperative hypertension and acute ischaemic heart disease, doses of <300 µg/kg/min, administered by continuous intravenous infusion, are used.
The principal adverse effect of esmolol is hypotension (incidence of 0 to 50%), which is frequently accompanied with diaphoresis. The incidence of hypotension appears to increase with doses exceeding 150 µg/kg/min and in patients with low baseline blood pressure. Hypotension infrequently requires any intervention other than decreasing the dose or discontinuing the infusion. Symptoms generally resolve within 30 minutes after discontinuing the drug. In surgical and critical care settings where clinical conditions are rapidly changing, the pharmacokinetic profile of esmolol allows the drug to provide rapid pharmacological control and minimises the potential for serious adverse effects.
Similar content being viewed by others
References
Erhardt PW, Woo CM, Anderson WG, et al. Ultra-short-acting β-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function. J Med Chem 1982; 25: 1408–12
Quon CY, Khoung M, Patil G, et al. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988; 16: 425–8
Anaquest Inc., Brevibloc package insert. Liberty Corner, NJ; 1993
Achari R, Drissel D, Thomas D, et al. Analysis of esmolol in human blood by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr 1988; 424: 430–4
Sum CY, Yacobi A. Gas chromatographic-mass spectrometric assay for the ultra-short-acting β-blocker esmolol. J Pharm Sci 1984; 73: 1177–9
Lee Y, Baaske DM, Alam AS. High-performance liquid Chromatographic method for the determination of esmolol hydrochloride. J Pharm Sci 1984; 73: 1660–1
Fan C, Zhao H, Chow MS. Simple and rapid high-performance liquid Chromatographic assay for esmolol. J Chromatogr 1991; 570: 217–23
de Bruijn NP, Reves JG, Croughwell N, et al. Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy. Anesthesiology 1987; 66: 323–6
Wiest DB, Trippel DL, Gillette PC, et al. Pharmacokinetics of esmolol in children. Clin Pharmacol Ther 1991; 49: 618–23
Flaherty JF, Wong B, La Follette G, et al. Pharmacokinetics of esmolol and ASL-8123 in renal failure. Clin Pharmacol Ther 1989; 45: 321–27
Jacobs JR, Croughwell ND, Goodman DK, et al. Effect of hypothermia and sampling site on blood esmolol concentrations. J Clin Pharmacol 1993; 33: 360–5
Greenspan AM, Spielman SR, Horowitz LN, et al. The electrophysiologic properties of esmolol, a short acting beta-blocker. Int J Clin Pharmacol Ther Toxicol 1988; 26: 209–16
Trippel DL, Wiest DB, Gillette PC. Cardiovascular and anti-arrhythmic effects of esmolol in children. J Pediatr 1991; 119: 142–7
Reilly CS, Wood M, Koshakji RP, et al. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade. Clin Pharmacol Ther 1985; 38: 579–85
Man in’t Veld AJ, Schalekamp MADH. How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists: a clue to the nature of their anti-hypertensive mechanism. Br J Clin Pharmacol 1982; 13 (Suppl. 1): 245S–57S
Deegan R, Wood A. β-Receptor antagonism does not fully explain esmolol-induced hypotension. Clin Pharmacol Ther 1994; 56: 223–8
Askenazi J, MacCosbe P, Hoff J, et al. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker. J Clin Pharmacol 1987; 27: 567–73
Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I). Clin Pharmacokinet 1989; 17: 175–99
Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II). Clin Pharmacokinet 1989; 17: 275–90
Sum CY, Yacobi A, Kartzinel R, et al. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983; 34: 427–34
Quon CY, Stampfli HF. Biochemical properties of blood esmolol esterase. Drug Metab Dispos 1985; 13: 420–4
Achari R, Drissel D, Matier WL, et al. Metabolism and urinary excretion of esmolol in humans. J Clin Pharmacol 1986; 26: 44–7
Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 1986; 26 (Suppl. A): A3–14
Lowenthal DT, Porter RS, Saris SD, et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol 1985; 56: 14F–17F
Buchi KN, Rollins DE, Tolman KG, et al. Pharmacokinetics of esmolol in hepatic disease. J Clin Pharmacol 1987; 27: 880–4
Wiest DB, Garner SS, Uber WE, et al. Pharmacokinetics of esmolol in pediatric post-cardiac surgery patients [abstract]. Clin Pharmacol Ther 1993; 53: 145
Murthy VS, Patel KD, Elangovan RG, et al. Effects of esmolol on circulatory response to intubation and succinylcholine-induced neuromuscular blockade in man [abstract]. Anesthesiology 1985; 63: A361
Lowenthal DT, Porter RS, Achari R, et al. Esmolol-digoxin drug interaction. J Clin Pharmacol 1987; 27: 561–6
Sheppard S, Eagle CJ, Strunin L. A bolus dose of esmolol attenuates tachycardia and hypertension after tracheal intubation. Can J Anaesth 1990; 37: 202–5
Oxorn D, Knox JW, Hill J. Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia. Can J Anaesth 1990; 37: 206–9
Miller DR, Martineau RJ, Hill J. Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian multicentre trial. Can J Anaesth 1991; 38: 849–58
Dyson A, Isaac PA, Pennant JH, et al. Esmolol attenuates cardiovascular responses to extubation. Anesth Analg 1990; 71: 675–8
Reves JG, Goughwell ND, Hawkins E, et al. Esmolol for treatment of intraoperative tachycardia and/or hypertension in patients having cardiac operations. J Thorac Cardiovasc Surg 1990; 100: 221–7
Gray RJ, Bateman TM, Czer LS, et al. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol 1987; 59: 887–91
Vincent RN, Click LA, Williams HM, et al. Esmolol as an adjunct in the treatment of systemic hypertension after operative repair of coarctation of the aorta. Am J Cardiol 1990; 65: 941–3
Smerling A, Gersony WM. Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med 1990; 18: 1288–90
Muzzi DA, Black S, Losasso TJ, et al. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg 1990; 70: 68–71
Gibson BE, Black S, Maass L, et al. Esmolol for the control of hypertension after neurologic surgery. Clin Pharmacol Ther 1988; 44: 650–3
Anderson S, Blanski L, Bryd RC, et al. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. Am Heart J 1986; 111: 42–8
Abrams J, Allen J, Allin D, et al. Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial. Am Heart J 1985; 110: 913–22
Borgstrom L, Johansson C, Larsson H, et al. Pharmacokinetics of propranolol. J Pharmacokinet Biopharm 1981; 9: 419–29
Shand DG, Nuckolls EM, Oates JA. Plasma propranolol levels in adults. Clin Pharmacol Ther 1970; 11: 112–20
Cheymol G, Poirier J, Barre J, et al. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 1987; 27: 874–9
Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63: 925–9
Shettigar UR, Toole G, Appunn D. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J 1993; 126: 368–74
The Esmolol Research Group. Intravenous esmolol for the treatment of supraventricular tachyarrhythmia: results of a multicenter, baseline-controlled safety and efficacy study in 160 patients. Am Heart J 1986; 112: 498–505
Kirshenbaum JM, Kloner RF, McGowan N, et al. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy. J Am Coll Cardiol 1988; 12: 773–80
Iskandrian AS, Bemis CE, Hakki AH, et al. Effects of esmolol on patents with left ventricular dysfunction. J Am Coll Cardiol 1986; 8: 225–31
Frishman W, Silverman R, Strom J, et al. Clinical pharmacology of the new beta-adrenergic blocking drugs: part 4. Adverse effects: choosing a β-adrenoreceptor blocker. Am Heart J 1979; 98: 256–62
Julian DG. Can beta-blockers be safely used in patients with recent mycocardial infarction with congestive heart failure? Circulation 1983; 67 (Suppl. I): 191
Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 1984; 69: 761–5
Wallis DE, Pope C, Littman WJ, et al. Safety and efficacy of esmolol for unstable angina pectoris. Am J Cardiol 1988; 62: 1033–37
Barth C, Ojile M, Pearson AC, et al. Ultra short-acting intravenous β-adrenergic blockade as add-on therapy in acute unstable angina. Am Heart J 1991; 121: 782–88
Ko W, Chu S. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients. J Am Coll Cardiol 1994; 23: 302–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiest, D. Esmolol. Clin. Pharmacokinet. 28, 190–202 (1995). https://doi.org/10.2165/00003088-199528030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199528030-00002